xbiotech
developing
true
human
antibody
combination
candidate
treatment
austin
texas
globe
newswire
xbiotech
nasdaq
xbit
announced
today
developing
new
breakthrough
candidate
therapy
calls
treating
illness
caused
combined
infections
influenza
global
spread
novel
virus
added
risk
flu
seasons
people
may
infected
influenza
viruses
two
viruses
superinfections
may
increase
severity
disease
complicate
treatment
fluvid
therapy
combine
xbiotech
breakthrough
influenza
true
human
antibodies
together
recently
discovered
antibodies
one
treatment
flu
season
approaches
amid
concerns
potential
deadly
twindemic
fluvid
urgently
needed
potential
breakthrough
therapy
treat
combined
infections
influenza
viruses
fluvid
could
used
provide
immunity
infection
treat
infections
occurred
fluvid
culmination
years
research
development
incorporates
extraordinary
influenza
antibodies
target
known
strains
influenza
combined
company
recently
discovered
antibody
passive
immunity
derived
patients
recovered
rapidly
virus
without
serious
illness
fluvid
harnesses
best
human
immunity
provide
expected
safe
effective
therapy
deadly
viruses
multiple
strains
influenza
responsible
seasonal
illnesses
pandemics
experienced
around
globe
however
among
multiple
influenza
strains
small
portions
virus
common
among
strains
years
xbiotech
scientists
diligently
screened
human
donors
antibodies
capable
targeting
regions
shared
among
influenza
viruses
identifying
antibodies
target
shared
areas
influenza
viruses
xbiotech
able
develop
single
therapy
could
used
treat
virtually
known
strains
xbiotech
vision
paid
discovery
antibodies
together
two
influenza
antibodies
neutralize
seasonal
influenza
strains
well
pandemic
influenza
strains
including
spanish
flu
infected
million
people
killed
million
worldwide
asian
flu
hong
kong
flu
killed
million
people
recent
california
virus
hong
kong
virus
prevalent
since
sporadic
persistent
avian
influenza
strains
addition
true
human
antibodies
target
influenza
strains
currently
widespread
poultry
speculated
future
pandemic
potential
humans
xbiotech
influenza
antibodies
therefore
target
virtually
known
influenza
strains
caused
widespread
disease
past
century
even
expected
neutralize
avian
influenza
strains
predicted
potential
infect
humans
future
fluvid
contain
antibodies
along
company
antibody
john
simard
xbiotech
president
ceo
commented
believe
combination
antibody
therapy
best
way
prepare
flu
season
larger
influenza
pandemic
outbreak
may
occur
combination
xbiotech
discovery
program
unlike
candidate
therapeutics
treat
infections
involve
multiple
pathogens
xbiotech
xbiotech
fully
integrated
global
biopharmaceutical
company
dedicated
pioneering
discovery
development
commercialization
therapeutic
antibodies
xbiotech
currently
advancing
pipeline
therapies
based
harnessing
naturally
occurring
antibodies
patients
immunity
certain
diseases
approach
use
natural
human
immunity
source
new
medicines
offers
potential
redefine
standards
care
wide
range
diseases
headquartered
austin
texas
xbiotech
also
leading
development
innovative
manufacturing
technology
reduce
cost
complexity
biological
drug
production
information
visit
true
therapeutic
antibodies
xbiotech
true
antibodies
available
antibodies
derived
without
modification
humans
possess
natural
immunity
certain
diseases
unlike
commercially
available
antibodies
called
humanized
fully
human
xbiotech
true
antibodies
directly
sourced
natural
human
immune
response
specific
diseases
without
modification
thereby
shown
cause
immunogenicity
discovery
clinical
programs
across
multiple
disease
areas
xbiotech
true
human
antibodies
potential
harness
body
natural
immunity
fight
disease
increased
safety
efficacy
tolerability
cautionary
note
statements
press
release
contains
statements
including
declarations
regarding
management
beliefs
expectations
involve
substantial
risks
uncertainties
cases
identify
statements
terminology
may
would
could
expects
plans
contemplate
anticipates
believes
estimates
predicts
projects
intend
continue
negative
terms
comparable
terminology
although
statements
contain
identifying
words
statements
subject
inherent
risks
uncertainties
predicting
future
results
conditions
could
cause
actual
results
differ
materially
projected
statements
risks
uncertainties
subject
disclosures
set
forth
risk
factors
section
certain
sec
filings
statements
guarantees
future
performance
actual
results
operations
financial
condition
liquidity
development
industry
operate
may
differ
materially
statements
contained
press
release
statements
make
press
release
speak
date
press
release
assume
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
contact
ashley
otero
aotero
